17 results about "Hypoxia reoxygenation" patented technology

The invention belongs to the field of medicines, and relates to a compound derived from Sinkiang lithospermum, a preparation method thereof and application of the compound in prevention and treatment of cardiovascular diseases. Specifically, the invention discloses a monoterpene benzoquinone derivative with a novel structure in Sinkiang lithospermum, a preparation method of the monoterpene benzoquinone derivative and application of the compound in preparation of anti-myocardial injury drugs. An in-vitro anti-myocardial cell injury activity experiment proves that the compound has a remarkable protection effect on isoprenaline (ISO)-induced H9C2 cell (rat embryo myocardial cell) injury and hypoxia-reoxygenation-induced H9C2 myocardial cell injury. The result shows that the compound can be used for preparing the anti-cardiovascular disease medicine.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The invention relates to a traditional Chinese medicine composition for treating myocardial ischemia-reperfusion injury and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine compositions. In order to solve the problem that a traditional Chinese medicine compound for treating myocardial ischemia-reperfusion injury is lacked in the prior art, the invention provides a traditional Chinese medicine composition for treating myocardial ischemia-reperfusion injury, and the traditional Chinese medicine composition comprises American ginseng, astragalus membranaceus, radix ophiopogonis, schisandra chinensis, radix rehmanniae recen, salvia miltiorrhiza, radix sophorae flavescentis, radix scrophulariae, honeysuckle, fructus forsythiae and liquorice. The traditional Chinese medicine composition provided by the invention has the effects of promoting blood circulation to remove blood stasis, reinforcing qi and nourishing yin, and activating meridians to stop pain, and is beneficial to improving the microcirculation state of cardiac muscle and relieving inflammatory response of cardiac muscle, so that damaged cardiac muscle tissues are protected. Animal experiments prove that the traditional Chinese medicine composition can effectively reduce the myocardial infarction area of MIRI model rats, remarkably improve the activity of myocardial cells subjected to hypoxia-reoxygenation injury and reduce the apoptosis rate of the myocardial cells subjected to hypoxia-reoxygenation injury. The invention provides a new way for clinical multi-target treatment of myocardial ischemia reperfusion injury.

The invention discloses application of 2-fluorofucose in preparation of a medicine for relieving acute kidney injury, and belongs to the technical field of biology. In-vitro cell experiments and animal experiments prove that 2-fluorofucose can inhibit core fucosylation, competitively inhibit the activity of fucosyltransferase, down-regulate the expression of FUT8 and reduce the core fucosylation level in kidney tissues and renal tubular epithelial cells; by inhibiting core fucosylation, effectively reversing EMT phenotypic transformation induced by hypoxia reoxygenation or ischemia reperfusion, up-regulating E-cadherin expression, down-regulating alpha-SMA and Snail expression and reducing cell migration ability, phosphorylation activation of an ERK pathway is remarkably inhibited, and downstream inflammatory factor release and cell injury signal transduction are blocked, so that the ERK pathway can be used for inhibiting ERK pathway phosphorylation activation. The invention provides application of 2-fluorofucose to preparation of a medicine for relieving acute kidney injury. The invention provides a new choice for treating acute kidney injury, has the outstanding advantages of remarkable curative effect, high safety and the like, and has a wide application prospect.

The invention provides a traditional Chinese medicine composition with functions of softening hardness and dredging collaterals as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition with the functions of softening hardness and dredging collaterals is prepared from the following raw material medicines in parts by weight: 20-40 parts of turtle shells, 20-40 parts of radix paeoniae alba, 14-22 parts of sedum sarmentosum, 9-21 parts of teasel roots, 9-21 parts of rhizoma acori graminei, 9-21 parts of astragalus membranaceus, 14-22 parts of ligusticum wallichii and 3-15g of honey-fried licorice roots. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition adopts a treatment method of softening hardness to dissipate stagnation, dredging collaterals and relieving spasm, and can improve clinical symptoms such as cognitive impairment related to small cerebral vasculopathy of a patient, and / or anxiety and depression, and / or sleep disorder and the like. In-vitro experiments prove that the traditional Chinese medicine composition has a protection effect on human brain microvascular endothelial cell injury caused by hypoxia and reoxygenation, and can promote cell proliferation and inhibit cell apoptosis. Therefore, the traditional Chinese medicine composition can be applied to prevention and / or treatment of clinical symptoms related to small cerebral vasculopathy under the pathological mechanism of pulse stagnation and collateral arthralgia.

The invention relates to the field of active substance extraction, and provides a preparation method of ganoderma ketonetriol and application of ganoderma ketonetriol in relieving cardiovascular hypoxia reoxygenation injury. The preparation method comprises the following steps: (1) carrying out ultrasonic extraction on a lucid ganoderma raw material to obtain an extract, wherein the ultrasonic power is 50-100 W; purifying the extract with macroporous resin to obtain a crude component; (2) sequentially carrying out primary separation and secondary separation on the crude component to obtain ganoderma ketonetriol; a C18 column of 40-60 [mu] m is used for the first separation, and the flow velocity of a mobile phase is 50-100 mL / min; a C18 column of 5-10 [mu] m is used in the second separation, and the flow velocity of the mobile phase is 20-40 mL / min; a mobile phase A of two times of separation is a trifluoroacetic acid aqueous solution, and a mobile phase B is acetonitrile. According to the method, ultrasonic extraction and macroporous resin purification are firstly carried out, and then two times of liquid phase separation are carried out, so that the preparation yield and purity of ganoderma ketonetriol are remarkably improved. The prepared ganoderma lucidum ketonetriol can relieve cardiovascular hypoxia reoxygenation injury.

The application discloses a traditional Chinese medicine composition, a medicine preparation and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises herba rhizomatosi and herba rhizomatosi, and the mass ratio of the herba rhizomatosi and the herba rhizomatosi is 1:1. The traditional Chinese medicine composition, the medicine preparation and the application thereof are based on the compatibility of the kidney-nourishing and heart-nourishing theory of traditional Chinese medicine, utilize the herba rhizomatosi and the herba rhizomatosi to form a kidney-yang tonifying traditional Chinese medicine pair, and are consistent with the core pathogenesis of MIRI. The corresponding traditional Chinese medicine composition of the traditional Chinese medicine pair can inhibit cell apoptosis, reduce the level of inflammatory factors in cells, relieve calcium ion overload and improve cell survival rate, so as to improve the hypoxia / reoxygenation-induced H9C2 myocardial cell damage state in multiple dimensions. The traditional Chinese medicine composition can activate estrogen receptors to inhibit the expression of related proteins in the endoplasmic reticulum stress signal pathway, and simultaneously regulate the expression of apoptosis-related proteins, thereby laying a foundation for the application of phytoestrogen therapy in the field of cardiovascular diseases and having significant clinical transformation value and market potential.

The present invention belongs to the field of biomedical technology, and specifically relates to an lncRNA-HRAT and its application. The present invention simulates the in vivo ischemia / reperfusion process through an hypoxia / reoxygenation (H / R) model, and then screens for lncRNAs with large differences in expression levels before and after H / R treatment through high-throughput sequencing technology. Finally, the lncRNA-HRAT is screened out. The lncRNA-HRAT provided by the present invention can be used as a biomarker for diseases such as myocardial infarction and myocardial ischemia-reperfusion injury, with high sensitivity, capable of detecting myocardial infarction and myocardial ischemia-reperfusion injury diseases and having high diagnostic efficiency and good reliability, providing a new detection method for diagnosing myocardial infarction and myocardial ischemia-reperfusion injury diseases. The detection method is simple and easy to operate, and has good potential for translational medicine prospects.

The invention provides application of phloretin in preparation of a medicine for preventing or treating renal ischemia-reperfusion injury, and belongs to the technical field of medical application. According to the application, research finds that the phloretin can up-regulate the protein expression level of PAK3 and reduce the apoptosis level under the conditions of renal ischemia reperfusion or hypoxia reoxygenation. On the basis, the phloretin or the pharmaceutically acceptable salt, ester or solvate thereof not only can be used as an activator of PAK3, but also can effectively inhibit cell apoptosis induced by renal ischemia reperfusion or hypoxia reoxygenation, so that a relatively good prevention and treatment effect on renal ischemia reperfusion injury caused by cell apoptosis is achieved. The application not only provides a new application for phloretin, but also provides a new drug choice for activation of PAK3, inhibition of apoptosis and renal ischemia-reperfusion injury, and has important guiding significance for prevention and treatment of renal ischemia-reperfusion injury.

The application aims to provide an application of a biological agent in treating placental dysfunction, and belongs to the technical field of medicine.The biological agent is composed of siRNA for inhibiting expression of a LOC101929800 gene, a transcript sequence of the LOC101929800 gene is SEQ ID NO.1 in the sequence listing, and a sequence of the siRNA is SEQ ID NO.10 and SEQ ID NO.11 in the sequence listing.The application finds that the siRNA can reverse the decrease of the invasion ability of the trophoblast cells caused by hypoxia-reoxygenation to a certain extent by transfecting the siRNA in the cells under hypoxia-reoxygenation, and therefore the siRNA can be used for preparing the biological agent for treating placental injury.

The invention relates to a pharmaceutical composition for treating myocardial ischemia-reperfusion injury, and belongs to the technical field of pharmaceutical compositions. In order to solve the problems that an existing myocardial ischemia-reperfusion injury treatment method is single in target spot and limited in mitochondrial function protection curative effect, the invention provides a pharmaceutical composition for treating myocardial ischemia-reperfusion injury, and the pharmaceutical composition comprises a component of glycyrrhiza spinosa chalcone derived from liquorice and a component of tanshinone IIA derived from salvia miltiorrhiza. In-vitro experiments prove that through compatibility of the licochalcone and the tanshinone IIA, the apoptosis of H9C2 cells after hypoxia reoxygenation injury can be relieved, the number of mitochondria in the H9C2 cells after hypoxia reoxygenation injury is effectively increased, the total ROS content and the mitochondria superoxide level in model cells are reduced, the mitochondria function and the mitochondria membrane potential in the model cells are effectively improved, and the effect of inhibiting hypoxia reoxygenation injury is achieved. Based on the effect of the composition on the aspect of protecting the mitochondrial function, clinical application of the composition on myocardial ischemia reperfusion injury can be further developed.

The invention belongs to the field of biological medicines, and discloses application of a Meis1 inhibitor in preparation of a medicine for relieving acute renal tubule injury. Aiming at the clinical problem that acute kidney injury (AKI) lacks a specific drug, the invention firstly discovers that marrow cytophilic virus integration site 1 (Meis1) is obviously up-regulated in AKI kidney tissues, and a folic acid (FA) and ischemia reperfusion (IR) double-animal model proves that the Mis1 inhibitor MEISi-2 (0.1-1mg / kg) is given; and intraperitoneal injection is carried out 1 day to 2 days before injury), so that the serum creatinine can be obviously reduced, the pathological injury of renal tubules (PAS score is more than or equal to 50%) can be improved, and injury markers KIM-1 / NGAL and apoptotic protein Cleaved Caspase 3 can be inhibited. In-vitro experiments further prove that MEISi-2 (1 [mu] M) can relieve apoptosis of renal tubular epithelial cells induced by hypoxia and reoxygenation (the apoptosis rate reaches 21.9%) by inhibiting Meis1. The invention also provides a pharmaceutical composition containing MEISi-2 (10-100 [mu] g / mL) and a normal saline injection preparation. The scheme is high in safety (no liver and kidney cardiotoxicity is found), and a brand new means is provided for targeted therapy of AKI.

This invention provides a gas control device for experiments involving hypoxia / reoxygenation of cardiomyocytes. [Solution] The system comprises three parallel intake branch pipes 4 integrating a precision needle-type throttling structure, a multi-stage mixing chamber 6 connected thereto, a gradient switching mechanism, and a pressure balancing device. The gradient switching mechanism includes a fixed plate 9 and a movable plate, with multiple throttling holes of different diameters in the fixed plate and gas passage holes in the movable plate, allowing the airflow cross-sectional area to be switched in steps by rotating the movable plate. This solves the problem of pressure fluctuations during gas environment switching interfering with cellular responses, achieves highly accurate and smooth switching between hypoxia and reoxygenation, eliminates instantaneous pressure pulses, provides an accurate and uniform mixed gas for the hypoxia / reoxygenation (H / R) model, and is applicable to molecular mechanism studies of myocardial ischemia-reperfusion injury (MIRI).

The invention belongs to the technical field of prevention and treatment of ventricular remodeling after ACS (acute coronary syndrome), and particularly relates to application of linoleoyl carnitine in screening of a medicine with an adjusting effect on post-PCI pro-inflammatory phase extension of an ACS patient, a screening method and the medicine. Research finds that the content of linoleoyl carnitine in plasma of an ACS patient after PCI can reflect the myocardial ischemia injury degree and can aggravate activity inhibition of hypoxia / reoxygenation on myocardial cells for the first time, so that the linoleoyl carnitine can be used for screening drugs with an adjusting effect on prolonging of the proinflammatory period of the ACS patient after PCI. Based on the complex balance relation between the proinflammatory period and the anti-inflammatory repair period, the invention provides a method for reversely screening the medicine with the regulating effect on the extension of the proinflammatory period after the PCI of the ACS patient, and the screened medicine can be used for regulating the polarization of Mo and inhibiting the extension of the proinflammatory period, so that the adverse remodeling of the heart after the ACS is relieved, and the effective recovery of the heart function is promoted.

The invention relates to the technical field of biology, and particularly discloses a preparation method and application of serum exosomes after electroacupuncture, and the method comprises the following steps: establishing a rat myocardial ischemia reperfusion injury model; applying electroacupuncture stimulation with current of 1mA, frequency of 2Hz and sparse and dense waves to'neiguan 'acupoints on two sides of the rat; serum is collected, and exosomes are extracted through a differential centrifugation method and an ultracentrifugation method; identifying form, particle size and surface marker proteins CD9 and CD81 of the extracted exosome by using a transmission electron microscope and a nanoflow detection technology; the exosome can be internalized by H9c2 myocardial cells, the survival rate of hypoxia / reoxygenation damaged myocardial cells is improved, and the levels of lactic dehydrogenase, creatine kinase and creatine kinase isoenzyme in cell supernatant are reduced. According to the scheme provided by the invention, a novel post-acupuncture serum exosome for treating myocardial ischemia reperfusion injury is provided, and the exosome effectively plays an acupuncture-like role in a treatment process, so that an effect of relieving myocardial ischemia reperfusion is achieved.

The invention discloses application of PPD derivatives as shown in formulas (I), (II) and (III) and pharmaceutically acceptable salts thereof in preparation of anti-hypoxia reoxygenation injury drugs, anti-ischemic injury drugs or health care products. The derivatives of the ginsenoside PPD are found to have myocardial ischemia-reperfusion injury resisting activity for the first time and show good ischemic injury resisting effect and ischemia-reperfusion injury resisting effect, compared with a model group, the survival rate of cells is remarkably increased, the relative activity of the ginsenoside PPD is superior to that of PPD, cytotoxicity does not occur, and the ginsenoside PPD has good development and application value. # imgabs0 #

The invention discloses an application of an LECT2 / Tie1 / Src signal channel in preparation of a medicine for preventing and treating endothelial cell injury. Research finds that LECT2 is combined with Tie1 to activate Src kinase to aggravate hypoxia and reoxygenation injury of vascular endothelial cells, so that liver ischemia reperfusion injury is aggravated. The Lect2 knocks down to relieve vascular endothelial cell injury, and the LECT2 recombinant protein aggravates vascular endothelial cell injury. Tie1 is knocked down, a TieIg3 segment recombinant protein inhibits LECT2 / Tie1 binding, and an Src inhibitor can relieve hypoxia injury of vascular endothelial cells. Liver ischemia reperfusion injury of the Lect2 knockout mouse is relieved, and vascular endothelial cell injury is relieved. The invention discloses a new mechanism of LECT2 / Tie1 / Src signal regulation and control of vascular endothelial cell hypoxia-reoxygenation injury, and provides a new target and strategy for treatment of liver ischemia-reperfusion injury.